Literature DB >> 447799

Conventional supervoltage irradiation is an effective treatment for acromegaly.

R C Eastman, P Gorden, J Roth.   

Abstract

Forty-seven acromegalic patients were treated with conventional supervoltage irradiation (4000-5000 rads) and were followed-up at 2, 5, and 10 yr after treatment. The mean fall in the GH concentrations 5 years after treatment was 77%, and GH was less than 10 ng/ml in 73% of the cases. In the majority, GH continued to fall over the 5- to 10-yr interval after treatment, so that by 10 yr, plasma GH was less than or equal to 10 ng/ml in 81% and less than or equal to 5 ng/ml in 69% of the patients. Also, the subjective (acral and facial changes) and the objective (metabolic) effects of GH excess all showed significant improvement with time, and the improvement roughly paralleled the fall in plasma GH concentrations. After therapy, no patient developed extrasellar extension, and headaches improved in the majority of patients. The prevalence of hypopituitarism, which was low before treatment, increased progressively throughout the follow-up period. Significant loss of vision was observed in only one patient, who received 5600 rads and had severe systemic sarcoidosis. The only other complication was temporal hair loss. Conventional super-voltage irradiation by 5-10 yr produces the same fall in plasma GH as all other forms of treatment for acromegaly, including transphenoidal microsurgery. The rate of fall in plasma GH after conventional irradiation is comparable to that of more aggressive forms of irradiation and is slower than that achieved by surgical methods but probably conventional irradiation has fewer serious side effects.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 447799     DOI: 10.1210/jcem-48-6-931

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  25 in total

1.  Delayed radiation necrosis of the central nervous system in patients irradiated for pituitary tumours.

Authors:  P J Grattan-Smith; J G Morris; A O Langlands
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

2.  The management of pituitary tumours and post-operative visual deterioration.

Authors:  C B Adams
Journal:  Acta Neurochir (Wien)       Date:  1988       Impact factor: 2.216

Review 3.  Therapeutic applications of bromocriptine in endocrine and neurological diseases.

Authors:  K Y Ho; M O Thorner
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

4.  Recent developments in the treatment of acromegaly.

Authors:  D K Lüdecke
Journal:  Neurosurg Rev       Date:  1985       Impact factor: 3.042

5.  Cost-of-illness study in acromegalic patients in Italy.

Authors:  G Didoni; S Grottol; V Gasco; M Battistini; D Ferone; M Giusti; F Ragazzoni; P Ruffo; E Ghigo; F Minuto
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

6.  A prospective multicenter octreotide dose response study in the treatment of acromegaly.

Authors:  S Ezzat; D A Redelmeier; M Gnehm; A G Harris
Journal:  J Endocrinol Invest       Date:  1995-05       Impact factor: 4.256

7.  Treatment of Cushing's disease with low dose radiation therapy.

Authors:  S R Ahmed; S M Shalet; C G Beardwell; M L Sutton
Journal:  Br Med J (Clin Res Ed)       Date:  1984-09-15

Review 8.  Acromegaly update--etiology, diagnosis and management.

Authors:  S Melmed; J A Fagin
Journal:  West J Med       Date:  1987-03

9.  Morphological effects in pituitary tumours following radiotherapy.

Authors:  M Anniko; J Wersäll
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1982

10.  Evaluation of a repeatable depot-bromocriptine preparation(Parlodel LAR) for the treatment of acromegaly.

Authors:  U Plöckinger; H J Quabbe
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.